Table 2

 Head to head comparisons between different β blockers (reported as point estimates of odds ratios or weighted mean differences with 95% credible intervals, with number of studies contributing to network)

AgentOdds ratioChange in LVEF (%) (secondary outcome) (n=10) (weighted mean difference)
Death (primary outcome) (n=21)Cardiovascular death (secondary outcome) (n=13)Sudden death (secondary outcome) (n=12)Drug discontinuation (secondary outcome) (n=21)
Any β blocker versus placebo/standard treatment:
 Standard pair-wise frequentist analysis0.71 (0.64 to 0.80)0.76 (0.70 to 0.84)0.73 (0.61 to 0.88)0.88 (0.78 to 0.98)4.2% (3.1% to 4.9%)
 Bayesian analysis0.69 (0.56 to 0.80)0.71 (0.49 to 0.95)0.70 (0.49 to 0.92)1.12 (0.99 to 1.31)4.1% (3.4% to 4.8%)
Atenolol versus:
 Placebo/standard treatment0.53 (0.15 to 1.83)0.64 (0.11 to 3.60)0.41 (0.05 to 2.82)0.75 (0.39 to 1.41)NA
 Bisoprolol0.83 (0.22 to 2.94)0.90 (0.12 to 6.42)0.64 (0.06 to 5.16)0.80 (0.39 to 1.61)NA
 Bucindolol0.62 (0.16 to 2.22)0.79 (0.10 to 6.05)0.49 (0.05 to 4.44)0.59 (0.18 to 1.85)NA
 Carvedilol0.95 (0.25 to 3.33)1.30 (0.19 to 8.85)0.73 (0.09 to 6.36)0.91 (0.46 to 1.79)NA
 Metoprolol0.76 (0.20 to 2.70)0.76 (0.09 to 5.31)0.46 (0.05 to 4.09)0.89 (0.45 to 1.75)NA
 Nebivolol0.62 (0.16 to 2.27)0.74 (0.09 to 5.15)0.68 (0.06 to 6.96)0.72 (0.35 to 1.51)NA
Bisoprolol versus:
 Placebo/standard treatment0.65 (0.47 to 0.89)0.70 (0.28 to 1.79)0.65 (0.25 to 1.84)0.94 (0.70 to 1.20)NA
 Bucindolol0.74 (0.44 to 1.27)0.86 (0.22 to 3.59)0.76 (0.19 to 3.63)0.75 (0.26 to 1.96)NA
 Carvedilol1.15 (0.79 to 1.69)1.42 (0.46 to 4.85)1.10 (0.40 to 5.16)1.15 (0.83 to 1.54)NA
 Metoprolol0.93 (0.61 to 1.39)0.84 (0.20 to 3.06)0.73 (0.18 to 3.29)1.12 (0.77 to 1.56)NA
 Nebivolol0.76 (0.44 to 1.23)0.83 (0.21 to 3.10)1.07 (0.21 to 5.93)0.91 (0.61 to 1.41)NA
Bucindolol versus:
 Placebo/standard treatment0.87 (0.57 to 1.28)0.82 (0.28 to 2.23)0.86 (0.28 to 2.43)1.26 (0.50 to 3.40)4.5% (4.1% to 4.8%)
 Carvedilol1.53 (0.98 to 2.43)1.65 (0.47 to 6.11)1.46 (0.44 to 6.49)1.54 (0.59 to 4.17)0.3% ( to 3.7% to 4.2%)
 Metoprolol1.23 (0.76 to 2.04)0.98 (0.21 to 3.78)0.96 (0.19 to 4.26)1.51 (0.57 to 4.16)0.9% (−2.8% to 4.6%)
 Nebivolol1.02 (0.56 to 1.75)0.96 (0.21 to 3.78)1.42 (0.24 to 7.46)1.22 (0.46 to 3.57)2.0% (−2.0% to 5.9%)
Carvedilol versus:
 Placebo/standard treatment0.56 (0.44 to 0.71)0.49 (0.22 to 0.97)0.58 (0.21 to 1.11) 0.83 (0.67 to 0.99)4.2% (2.0% to 6.4%)
 Metoprolol0.80 (0.59 to 1.08)0.59 (0.20 to 1.39)0.67 (0.19 to 1.49)0.99 (0.75 to 1.23)0.6% (−2.1% to 3.4%)
 Nebivolol0.66 (0.39 to 1.02)0.58 (0.16 to 1.80)0.97 (0.17 to 3.71)0.79 (0.56 to 1.20)1.7% (−1.1% to 4.5%)
Metoprolol versus:
 Placebo/standard treatment0.71 (0.53 to 0.92)0.84 (0.32 to 2.41)0.90 (0.31 to 2.59)0.84 (0.67 to 1.06)3.6% (1.9% to 5.2%)
 Nebivolol0.82 (0.49 to 1.32)0.98 (0.25 to 4.06)0.68 (0.27 to 8.25)0.80 (0.57 to 1.28)1.1% (−1.7% to 3.8%)
Nebivolol versus placebo/standard treatment0.78 (0.43 to 1.33)0.85 (0.33 to 2.32)0.61 (0.16 to 2.29)1.04 (0.71 to 1.38)2.5% (0.3% to 4.7%)

LVEF=left ventricular ejection fraction; NA=not available or applicable or reported.